REGISTERED
on 18 Jun 2019
Last Applicant/ Owned by
400 Oyster Point Boulevard, Suite 505
South San Francisco
CA
94080
Serial Number
87278812 filed on 22nd Dec 2016
Registration Number
5782129 registered on 18th Jun 2019
Correspondent Address
Jennifer Lee Taylor
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
T TITAN PHARMACEUTICALS
Pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune syst Read More
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases
First Use Date in General
26th Feb 2019
First Use Date in Commerce
26th Feb 2019
Mark Details
Serial Number
No 87278812
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 304146023000
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Design Code(s)
26.01.02 -
Plain single line circles
26.01.21 -
Circles that are totally or partially shaded
26.05.08 -
Letters, numerals or punctuation forming the perimeter of a triangle, bordering the perimeter of a triangle or forming a triangle
26.05.21 -
Triangles that are completely or partially shaded
27.03.01 -
Geometric figures forming letters or numerals, including punctuation
Legal History
| Status Date | Action Taken |
|---|---|
| 18th Jun 2024 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| 18th Jun 2019 | REGISTERED-PRINCIPAL REGISTER |
| 17th May 2019 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 16th May 2019 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 05th May 2019 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 05th May 2019 | STATEMENT OF USE PROCESSING COMPLETE |
| 23rd Apr 2019 | USE AMENDMENT FILED |
| 23rd Apr 2019 | TEAS STATEMENT OF USE RECEIVED |
| 19th Apr 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 17th Apr 2019 | SOU EXTENSION 1 GRANTED |